时间:2021-02-03 14:07:50人气:4716来源: 欧中之声
A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
Cloud seas engulf Danxia, earthly realm cradles celestial | MicroInPixels
(13220)人喜欢2025-04-07Guangzhou unveils new city image promo video
(9037)人喜欢2025-04-04News Xplained | How Guangdong is supercharging AI and robots
(7693)人喜欢2025-04-03Beidi Festival activities held in Foshan’s Xiqiao Town
(14361)人喜欢2025-04-02Guangxi's Sanyuesan Festival flourishes with culture, song, and romance
(14367)人喜欢2025-04-01Italian delegation explores Guangzhou, strengthening educational and cultural ties
(9066)人喜欢2025-03-31Discover poetic Yunfu in AI-generated Chinese ink brush painting video
(15482)人喜欢2025-03-29Get recharged at Art Week Shenzhen
(9060)人喜欢2025-03-26